Consequently, the inhibition of acetylcholinesterase (AChE), the main enzyme responsible for ACh hydrolysis, emerged as a central strategy in AD drug development, aiming to elevate ACh levels in the brain [5,6]. Here, ACHE is linked to Alzheimer disease.